1
|
Wang F, Zhou C, Zhu Y, Keshavarzi M. The microRNA Let-7 and its exosomal form: Epigenetic regulators of gynecological cancers. Cell Biol Toxicol 2024; 40:42. [PMID: 38836981 PMCID: PMC11153289 DOI: 10.1007/s10565-024-09884-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 05/15/2024] [Indexed: 06/06/2024]
Abstract
Many types of gynecological cancer (GC) are often silent until they reach an advanced stage, and are therefore often diagnosed too late for effective treatment. Hence, there is a real need for more efficient diagnosis and treatment for patients with GC. During recent years, researchers have increasingly studied the impact of microRNAs cancer development, leading to a number of applications in detection and treatment. MicroRNAs are a particular group of tiny RNA molecules that regulate regular gene expression by affecting the translation process. The downregulation of numerous miRNAs has been observed in human malignancies. Let-7 is an example of a miRNA that controls cellular processes as well as signaling cascades to affect post-transcriptional gene expression. Recent research supports the hypothesis that enhancing let-7 expression in those cancers where it is downregulated may be a potential treatment option. Exosomes are tiny vesicles that move through body fluids and can include components like miRNAs (including let-7) that are important for communication between cells. Studies proved that exosomes are able to enhance tumor growth, angiogenesis, chemoresistance, metastasis, and immune evasion, thus suggesting their importance in GC management.
Collapse
Affiliation(s)
- Fei Wang
- Haiyan People's Hospital, Zhejiang Province, Jiaxing, 314300, Zhejiang, China
| | - Chundi Zhou
- Haiyan People's Hospital, Zhejiang Province, Jiaxing, 314300, Zhejiang, China
| | - Yanping Zhu
- Haiyan People's Hospital, Zhejiang Province, Jiaxing, 314300, Zhejiang, China.
| | - Maryam Keshavarzi
- School of Medicine, Tehran University of Medical Sciences, Tehran, Tehran, Iran.
| |
Collapse
|
2
|
Frederick MI, Hovey OFJ, Kakadia JH, Shepherd TG, Li SSC, Heinemann IU. Proteomic and Phosphoproteomic Reprogramming in Epithelial Ovarian Cancer Metastasis. Mol Cell Proteomics 2023; 22:100660. [PMID: 37820923 PMCID: PMC10652129 DOI: 10.1016/j.mcpro.2023.100660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 09/30/2023] [Accepted: 10/05/2023] [Indexed: 10/13/2023] Open
Abstract
Epithelial ovarian cancer (EOC) is a high-risk cancer presenting with heterogeneous tumors. The high incidence of EOC metastasis from primary tumors to nearby tissues and organs is a major driver of EOC lethality. We used cellular models of spheroid formation and readherence to investigate cellular signaling dynamics in each step toward EOC metastasis. In our system, adherent cells model primary tumors, spheroid formation represents the initiation of metastatic spread, and readherent spheroid cells represent secondary tumors. Proteomic and phosphoproteomic analyses show that spheroid cells are hypoxic and show markers for cell cycle arrest. Aurora kinase B abundance and downstream substrate phosphorylation are significantly reduced in spheroids and readherent cells, explaining their cell cycle arrest phenotype. The proteome of readherent cells is most similar to spheroids, yet greater changes in the phosphoproteome show that spheroid cells stimulate Rho-associated kinase 1 (ROCK1)-mediated signaling, which controls cytoskeletal organization. In spheroids, we found significant phosphorylation of ROCK1 substrates that were reduced in both adherent and readherent cells. Application of the ROCK1-specific inhibitor Y-27632 to spheroids increased the rate of readherence and altered spheroid density. The data suggest ROCK1 inhibition increases EOC metastatic potential. We identified novel pathways controlled by Aurora kinase B and ROCK1 as major drivers of metastatic behavior in EOC cells. Our data show that phosphoproteomic reprogramming precedes proteomic changes that characterize spheroid readherence in EOC metastasis.
Collapse
Affiliation(s)
- Mallory I Frederick
- Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Owen F J Hovey
- Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Jenica H Kakadia
- Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Trevor G Shepherd
- Department of Obstetrics & Gynaecology, Western University, London, Ontario, Canada; London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada
| | - Shawn S C Li
- Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
| | - Ilka U Heinemann
- Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
| |
Collapse
|
3
|
Tomas E, Shepherd TG. Insights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems. J Ovarian Res 2023; 16:70. [PMID: 37038202 PMCID: PMC10088149 DOI: 10.1186/s13048-023-01145-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 03/28/2023] [Indexed: 04/12/2023] Open
Abstract
Epithelial ovarian cancer (EOC) research has become more complex as researchers try to fully understand the metastatic process. Especially as we delve into the concept of tumour dormancy, where cells transition between proliferative and dormant states to survive during disease progression. Thus, the in vitro models used to conduct this research need to reflect this vast biological complexity. The innovation behind the many three-dimensional (3D) spheroid models has been refined to easily generate reproducible spheroids so that we may understand the various molecular signaling changes of cells during metastasis and determine therapeutic efficacy of treatments. This ingenuity was then used to develop the 3D ex vivo patient-derived organoid model, as well as multiple co-culture model systems for EOC research. Although, researchers need to continue to push the boundaries of these current models for in vitro and even in vivo work in the future. In this review, we describe the 3D models already in use, where these models can be developed further and how we can use these models to gain the most knowledge on EOC pathogenesis and discover new targeted therapies.
Collapse
Affiliation(s)
- Emily Tomas
- London Regional Cancer Program, The Mary & John Knight Translational Ovarian Cancer Research Unit, 790 Commissioners Rd. E. Room A4-836, London, ON, N6A 4L6, Canada
- Department of Anatomy & Cell Biology, Western University, London, ON, Canada
| | - Trevor G Shepherd
- London Regional Cancer Program, The Mary & John Knight Translational Ovarian Cancer Research Unit, 790 Commissioners Rd. E. Room A4-836, London, ON, N6A 4L6, Canada.
- Department of Anatomy & Cell Biology, Western University, London, ON, Canada.
- Department of Obstetrics & Gynaecology, Western University, London, ON, Canada.
- Department of Oncology, Western University, London, ON, Canada.
| |
Collapse
|
4
|
Shepherd TG, Dick FA. Principles of dormancy evident in high-grade serous ovarian cancer. Cell Div 2022; 17:2. [PMID: 35321751 PMCID: PMC8944075 DOI: 10.1186/s13008-022-00079-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Accepted: 03/16/2022] [Indexed: 11/17/2022] Open
Abstract
In cancer, dormancy refers to a clinical state in which microscopic residual disease becomes non-proliferative and is largely refractory to chemotherapy. Dormancy was first described in breast cancer where disease can remain undetected for decades, ultimately leading to relapse and clinical presentation of the original malignancy. A long latency period can be explained by withdrawal from cell proliferation (cellular dormancy), or a balance between proliferation and cell death that retains low levels of residual disease (tumor mass dormancy). Research into cellular dormancy has revealed features that define this state. They include arrest of cell proliferation, altered cellular metabolism, and unique cell dependencies and interactions with the microenvironment. These characteristics can be shared by dormant cells derived from disparate primary disease sites, suggesting common features exist between them. High-grade serous ovarian cancer (HGSOC) disseminates to locations throughout the abdominal cavity by means of cellular aggregates called spheroids. These growth-arrested and therapy-resistant cells are a strong contributor to disease relapse. In this review, we discuss the similarities and differences between ovarian cancer cells in spheroids and dormant properties reported for other cancer disease sites. This reveals that elements of dormancy, such as cell cycle control mechanisms and changes to metabolism, may be similar across most forms of cellular dormancy. However, HGSOC-specific aspects of spheroid biology, including the extracellular matrix organization and microenvironment, are obligatorily disease site specific. Collectively, our critical review of current literature highlights places where HGSOC cell dormancy may offer a more tractable experimental approach to understand broad principles of cellular dormancy in cancer.
Collapse
Affiliation(s)
- Trevor G Shepherd
- London Regional Cancer Program, London Health Sciences Centre, London, ON, N6A 5W9, Canada.,Department of Obstetrics & Gynaecology, Western University, London, ON, N6A 5C1, Canada
| | - Frederick A Dick
- London Regional Cancer Program, London Health Sciences Centre, London, ON, N6A 5W9, Canada. .,Department of Pathology and Laboratory Medicine, Western University, London, ON, N6A 5C1, Canada. .,Children's Health Research Institute, London, ON, N6A 4V2, Canada.
| |
Collapse
|
5
|
miRNA-Dependent Regulation of AKT1 Phosphorylation. Cells 2022; 11:cells11050821. [PMID: 35269443 PMCID: PMC8909289 DOI: 10.3390/cells11050821] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 02/22/2022] [Accepted: 02/23/2022] [Indexed: 02/01/2023] Open
Abstract
The phosphoinositide-3-kinase (PI3K)/AKT pathway regulates cell survival and is over-activated in most human cancers, including ovarian cancer. Following growth factor stimulation, AKT1 is activated by phosphorylation at T308 and S473. Disruption of the AKT1 signaling pathway is sufficient to inhibit the epithelial-mesenchymal transition in epithelial ovarian cancer (EOC) cells. In metastatic disease, adherent EOC cells transition to a dormant spheroid state, characterized previously by low S473 phosphorylation in AKT1. We confirmed this finding and observed that T308 phosphorylation was yet further reduced in EOC spheroids and that the transition from adherent to spheroid growth is accompanied by significantly increased levels of let-7 miRNAs. We then used mechanistic studies to investigate the impact of let-7 miRNAs on AKT1 phosphorylation status and activity in cells. In growth factor-stimulated HEK 293T cells supplemented with let-7a, we found increased phosphorylation of AKT1 at T308, decreased phosphorylation at S473, and enhanced downstream AKT1 substrate GSK-3β phosphorylation. Let-7b and let-7g also deregulated AKT signaling by rendering AKT1 insensitive to growth factor simulation. We uncovered let-7a-dependent deregulation of PI3K pathway components, including PI3KC2A, PDK1, and RICTOR, that govern AKT1 phosphorylation and activity. Together, our data show a new role for miRNAs in regulating AKT signaling.
Collapse
|
6
|
Sales A, Khodr V, Machillot P, Chaar L, Fourel L, Guevara-Garcia A, Migliorini E, Albigès-Rizo C, Picart C. Differential bioactivity of four BMP-family members as function of biomaterial stiffness. Biomaterials 2022; 281:121363. [PMID: 35063741 PMCID: PMC7613911 DOI: 10.1016/j.biomaterials.2022.121363] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 12/28/2021] [Accepted: 01/03/2022] [Indexed: 12/15/2022]
Abstract
While a soft film itself is not able to induce cell spreading, BMP-2 presented via such soft film (so called "matrix-bound BMP-2") was previously shown to trigger cell spreading, migration and downstream BMP-2 signaling. Here, we used thin films of controlled stiffness presenting matrix-bound BMPs to study the effect of four BMP members (BMP-2, 4, 7, 9) on cell adhesion and differentiation of skeletal progenitors. We performed automated high-content screening of cellular responses, including cell number, cell spreading area, SMAD phosphorylation and alkaline phosphatase activity. We revealed that the cell response to bBMPs is BMP-type specific, and involved certain BMP receptors and beta chain integrins. In addition, this response is stiffness-dependent for several receptors. The basolateral presentation of the BMPs allowed us to discriminate the specificity of cellular response, especiallyd the role of type I and II BMP receptors and of β integrins in a BMP-type and stiffness-dependent manner. Notably, BMP-2 and BMP-4 were found to have distinct roles, while ALK5, previously known as a TGF-β receptor was revealed to be involved in the BMP-pathway.
Collapse
Affiliation(s)
- Adrià Sales
- Univ. Grenoble Alpes, CEA, INSERM U1292 Biosanté, CNRS EMR 5000 BRM, 38000 Grenoble, France; CNRS, Grenoble Institute of Technology, LMGP, UMR 5628, 3 Parvis Louis Néel, 38016, Grenoble, France.
| | - Valia Khodr
- Univ. Grenoble Alpes, CEA, INSERM U1292 Biosanté, CNRS EMR 5000 BRM, 38000 Grenoble, France; CNRS, Grenoble Institute of Technology, LMGP, UMR 5628, 3 Parvis Louis Néel, 38016, Grenoble, France
| | - Paul Machillot
- Univ. Grenoble Alpes, CEA, INSERM U1292 Biosanté, CNRS EMR 5000 BRM, 38000 Grenoble, France; CNRS, Grenoble Institute of Technology, LMGP, UMR 5628, 3 Parvis Louis Néel, 38016, Grenoble, France
| | - Line Chaar
- Univ. Grenoble Alpes, INSERM U1209, CNRS 5309, Institute for Advanced Biosciences (IAB) 38000 Grenoble, France
| | - Laure Fourel
- Univ. Grenoble Alpes, CEA, INSERM U1292 Biosanté, CNRS EMR 5000 BRM, 38000 Grenoble, France; CNRS, Grenoble Institute of Technology, LMGP, UMR 5628, 3 Parvis Louis Néel, 38016, Grenoble, France; Univ. Grenoble Alpes, INSERM U1209, CNRS 5309, Institute for Advanced Biosciences (IAB) 38000 Grenoble, France
| | - Amaris Guevara-Garcia
- Univ. Grenoble Alpes, CEA, INSERM U1292 Biosanté, CNRS EMR 5000 BRM, 38000 Grenoble, France; CNRS, Grenoble Institute of Technology, LMGP, UMR 5628, 3 Parvis Louis Néel, 38016, Grenoble, France; Univ. Grenoble Alpes, INSERM U1209, CNRS 5309, Institute for Advanced Biosciences (IAB) 38000 Grenoble, France
| | - Elisa Migliorini
- Univ. Grenoble Alpes, CEA, INSERM U1292 Biosanté, CNRS EMR 5000 BRM, 38000 Grenoble, France; CNRS, Grenoble Institute of Technology, LMGP, UMR 5628, 3 Parvis Louis Néel, 38016, Grenoble, France
| | - Corinne Albigès-Rizo
- Univ. Grenoble Alpes, INSERM U1209, CNRS 5309, Institute for Advanced Biosciences (IAB) 38000 Grenoble, France
| | - Catherine Picart
- Univ. Grenoble Alpes, CEA, INSERM U1292 Biosanté, CNRS EMR 5000 BRM, 38000 Grenoble, France; CNRS, Grenoble Institute of Technology, LMGP, UMR 5628, 3 Parvis Louis Néel, 38016, Grenoble, France; Institut Universitaire de France (IUF), France.
| |
Collapse
|
7
|
Semertzidou A, Brosens JJ, McNeish I, Kyrgiou M. Organoid models in gynaecological oncology research. Cancer Treat Rev 2020; 90:102103. [PMID: 32932156 DOI: 10.1016/j.ctrv.2020.102103] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 08/29/2020] [Accepted: 08/31/2020] [Indexed: 02/06/2023]
Abstract
Cell culture and animal models represent experimental cornerstones for the investigation of tissue, organ and body physiology in the context of gynaecological research. However, their ability to accurately reflect human mechanisms in vivo is limited. The development of organoid technologies has begun to address this limitation by providing platforms ex vivo that resemble the phenotype and genotype of the multi-cellular tissue from which they were derived more accurately. In this review, we discuss advances in organoid derivation from endometrial, ovarian, fallopian tube and cervical tissue, both benign and malignant, the manipulation of organoid microenvironment to preserve stem cell populations and achieve long-term expansion and we explore the morphological and molecular kinship of organoids to parent tissue. Apart from providing new insight into mechanisms of carcinogenesis, gynaecological cancer-derived organoids can be utilised as tools for drug screening of chemotherapeutic and hormonal compounds where they exhibit interpatient variability consistent with states in vivo and xenografted tumours allowing for patient-tailored treatment strategies. Bridging organoid with bioengineering accomplishments is clearly the way forward to the generation of organoid-on-a-chip technologies enhancing the robustness of the model and its translational potential. Undeniably, organoids are expected to stand their ground in the years to come and revolutionize development and disease modelling studies.
Collapse
Affiliation(s)
- Anita Semertzidou
- Department of Surgery and Cancer & Department of Digestion, Metabolism and Reproduction, Faculty of Medicine, Imperial College London, London W12 0NN, UK; Queen Charlotte's and Chelsea - Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK
| | - Jan J Brosens
- Division of Biomedical Sciences, Clinical Science Research Laboratories, Warwick Medical School, University of Warwick, Coventry CV2 2DX, UK; Tommy's National Centre for Miscarriage Research, University Hospitals Coventry & Warwickshire, Coventry CV2 2DX, UK
| | - Iain McNeish
- Department of Surgery and Cancer & Department of Digestion, Metabolism and Reproduction, Faculty of Medicine, Imperial College London, London W12 0NN, UK
| | - Maria Kyrgiou
- Department of Surgery and Cancer & Department of Digestion, Metabolism and Reproduction, Faculty of Medicine, Imperial College London, London W12 0NN, UK; Queen Charlotte's and Chelsea - Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK.
| |
Collapse
|
8
|
Wang H, Ni Z, Yang J, Li M, Liu L, Pan X, Xu L, Wang X, Fang S. IL-1β promotes osteogenic differentiation of mouse bone marrow mesenchymal stem cells via the BMP/Smad pathway within a certain concentration range. Exp Ther Med 2020; 20:3001-3008. [PMID: 32855666 PMCID: PMC7444350 DOI: 10.3892/etm.2020.9065] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Accepted: 03/24/2020] [Indexed: 12/21/2022] Open
Abstract
Inflammatory factors play an important role in the process of fracture healing. The influence of interleukin (IL)-1β, a key inflammatory factory, on new bone formation has been controversial. The aim of the present study was to investigate whether IL-1β affects the osteogenic differentiation of mouse bone marrow mesenchymal stem cells (MBMMSCs), and examined its effective concentration range and molecular mechanism of action. MBMMSC proliferation in the presence of IL-1β was observed using a Cell-Counting Kit-8 assay, and the effect of IL-1β on MBMMSC apoptosis was examined via flow cytometry. Alkaline phosphatase assay, Alizarin Red staining and quantitative assays were performed to evaluate the osteogenic differentiation of MBMMSCs. The expression levels of osteogenic differentiation markers were detected using reverse transcription-quantitative PCR (RT-qPCR). It was demonstrated that within a concentration range of 0.01-1 ng/ml, IL-1β promoted osteogenic differentiation of MBMMSCs and did not induce apoptosis. Furthermore, RT-qPCR results indicated that IL-1β increased osteogenic gene expression within this concentration range. Moreover, Western blotting results identified that the bone morphogenetic protein/Smad (BMP/Smad) signaling pathway was significantly activated by IL-1β under osteogenic conditions. Therefore, the present results suggested that within a certain concentration range, IL-1β promoted osteogenic differentiation and function of MBMMSCs via the BMP/Smad signaling pathway.
Collapse
Affiliation(s)
- Hao Wang
- Department of Orthopedics, Huainan First People's Hospital, Anhui University of Science and Technology, Huainan, Anhui 232000, P.R. China.,Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
| | - Zhihao Ni
- Department of Orthopedics, Hefei First People's Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
| | - Jiazhao Yang
- Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
| | - Meng Li
- Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
| | - Lei Liu
- Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
| | - Xuejie Pan
- Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
| | - Lei Xu
- Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
| | - Xujin Wang
- Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
| | - Shiyuan Fang
- Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China
| |
Collapse
|
9
|
Laski J, Singha B, Wang X, Valdés YR, Collins O, Shepherd TG. Activated CAMKKβ-AMPK signaling promotes autophagy in a spheroid model of ovarian tumour metastasis. J Ovarian Res 2020; 13:58. [PMID: 32393385 PMCID: PMC7216359 DOI: 10.1186/s13048-020-00660-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Accepted: 05/04/2020] [Indexed: 02/08/2023] Open
Abstract
Background A hallmark of epithelial ovarian cancer (EOC) metastasis is the process of spheroid formation, whereby tumour cells aggregate into 3D structures while in suspension in the peritoneal cavity. EOC spheroids are subjected to bioenergetic stress, thereby activating AMP-activated protein kinase (AMPK) signaling to enter a metabolically quiescent state, which can facilitate cell survival under nutrient-limiting conditions. Independently, we have also demonstrated that EOC spheroids induce autophagy, a process that degrades and recycles intracellular components to restore energy and metabolites. Herein, we sought to examine whether AMPK controls autophagy induction as a cell survival mechanism in EOC spheroids. Results We observed a co-ordinate increase in phosphorylated AMPK and the autophagy marker LC3-II during EOC spheroid formation. Reduced AMPK expression by siRNA-mediated knockdown of PRKAA1 and PRKAA2 blocked autophagic flux in EOC spheroids as visualized by fluorescence microscopy using the mCherry-eGFP-LC3B reporter. A complementary approach using pharmacologic agents Compound C and CAMKKβ inhibitor STO-609 to inhibit AMPK activity both yielded a potent blockade of autophagic flux as well. However, direct activation of AMPK in EOC cells using oligomycin and metformin was insufficient to induce autophagy. STO-609 treatment of EOC spheroids resulted in reduced viability in 7 out of 9 cell lines, but with no observed effect in non-malignant FT190 cell spheroids. Conclusions Our results support the premise that CAMKKβ-mediated AMPK activity is required, at least in part, to regulate autophagy induction in EOC spheroids and support cell viability in this in vitro model of EOC metastasis.
Collapse
Affiliation(s)
- Jeremi Laski
- The Mary & John Knight Translational Ovarian Cancer Research Unit, Lawson Health Research Institute, London, ON, Canada.,Departments of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
| | - Bipradeb Singha
- The Mary & John Knight Translational Ovarian Cancer Research Unit, Lawson Health Research Institute, London, ON, Canada.,Departments of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
| | - Xu Wang
- The Mary & John Knight Translational Ovarian Cancer Research Unit, Lawson Health Research Institute, London, ON, Canada.,West China School of Medicine, Chengdu, Sichuan, China
| | - Yudith Ramos Valdés
- The Mary & John Knight Translational Ovarian Cancer Research Unit, Lawson Health Research Institute, London, ON, Canada
| | - Olga Collins
- The Mary & John Knight Translational Ovarian Cancer Research Unit, Lawson Health Research Institute, London, ON, Canada
| | - Trevor G Shepherd
- The Mary & John Knight Translational Ovarian Cancer Research Unit, Lawson Health Research Institute, London, ON, Canada. .,Departments of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. .,Departments of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. .,Departments of Obstetrics & Gynaecology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. .,London Regional Cancer Program, 790 Commissioners Rd. E., Room A4-836, London, ON, N6A 4L6, Canada.
| |
Collapse
|
10
|
Kim YS, Gupta Vallur P, Jones VM, Worley BL, Shimko S, Shin DH, Crawford LC, Chen CW, Aird KM, Abraham T, Shepherd TG, Warrick JI, Lee NY, Phaeton R, Mythreye K, Hempel N. Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells. Oncogene 2020; 39:1619-1633. [PMID: 31723239 PMCID: PMC7036012 DOI: 10.1038/s41388-019-1097-7] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 10/28/2019] [Accepted: 11/04/2019] [Indexed: 12/20/2022]
Abstract
Tumor cells must alter their antioxidant capacity for maximal metastatic potential. Yet the antioxidant adaptations required for ovarian cancer transcoelomic metastasis, which is the passive dissemination of cells in the peritoneal cavity, remain largely unexplored. Somewhat contradicting the need for oxidant scavenging are previous observations that expression of SIRT3, a nutrient stress sensor and regulator of mitochondrial antioxidant defenses, is often suppressed in many primary tumors. We have discovered that this mitochondrial deacetylase is specifically upregulated in a context-dependent manner in cancer cells. SIRT3 activity and expression transiently increased following ovarian cancer cell detachment and in tumor cells derived from malignant ascites of high-grade serous adenocarcinoma patients. Mechanistically, SIRT3 prevents mitochondrial superoxide surges in detached cells by regulating the manganese superoxide dismutase (SOD2). This mitochondrial stress response is under dual regulation by SIRT3. SIRT3 rapidly increases SOD2 activity as an early adaptation to cellular detachment, which is followed by SIRT3-dependent increases in SOD2 mRNA during sustained anchorage-independence. In addition, SIRT3 inhibits glycolytic capacity in anchorage-independent cells thereby contributing to metabolic changes in response to detachment. While manipulation of SIRT3 expression has few deleterious effects on cancer cells in attached conditions, SIRT3 upregulation and SIRT3-mediated oxidant scavenging are required for anoikis resistance in vitro following matrix detachment, and both SIRT3 and SOD2 are necessary for colonization of the peritoneal cavity in vivo. Our results highlight the novel context-specific, pro-metastatic role of SIRT3 in ovarian cancer.
Collapse
Affiliation(s)
- Yeon Soo Kim
- Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Piyushi Gupta Vallur
- Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Victoria M Jones
- Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Beth L Worley
- Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Sara Shimko
- Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Dong-Hui Shin
- Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - LaTaijah C Crawford
- Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Chi-Wei Chen
- Department of Cellular and Molecular Physiology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Katherine M Aird
- Department of Cellular and Molecular Physiology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Thomas Abraham
- Department of Neural and Behavioral Sciences, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Trevor G Shepherd
- The Mary & John Knight Translational Ovarian Cancer Research Unit, Departments of Obstetrics & Gynecology Oncology and Anatomy & Cell Biology, Western University, London, ON, Canada
| | - Joshua I Warrick
- Department of Pathology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Nam Y Lee
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA
| | - Rebecca Phaeton
- Department of Obstetrics and Gynecology, and Microbiology and Immunology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
| | - Karthikeyan Mythreye
- Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC, USA.
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
| | - Nadine Hempel
- Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA, USA.
| |
Collapse
|
11
|
Epithelial‑mesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells. Mol Med Rep 2019; 19:1501-1508. [PMID: 30628686 PMCID: PMC6390058 DOI: 10.3892/mmr.2019.9814] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 10/19/2018] [Indexed: 01/04/2023] Open
Abstract
Bone morphogenetic protein 9 (BMP9) belongs to the transforming growth factor-β (TGF-β) superfamily, and has been reported to promote cancer cell proliferation and epithelial-mesenchymal transition (EMT). Cisplatin (DDP) is the first line treatment for ovarian cancer. However, initiation of EMT confers insensitivity to chemotherapy. The present study aimed to verify and examine the mechanisms underlying the effects of BMP9 on treatment with DDP for ovarian cancer. Prior to treatment with DDP, ovarian cancer cells were exposed to BMP9 for 3 days. Following this, cell viability, apoptosis rate and the extent of DNA damage were evaluated to compare the effects of DDP on BMP9-pretreated and non-pretreated ovarian cancer cells. In addition, EMT marker expression was evaluated by western blotting and immunofluorescence. The results demonstrated that BMP9 pretreatment inhibited the cytotoxicity of DDP on ovarian cancer cells. Additionally, BMP9-pretreated ovarian cancer cells had downregulated expression of the epithelial marker E-cadherin, which was accompanied by an upregulation of the mesenchymal markers N-cadherin, Snail, Slug, and Twist. Taken together, the findings of the present study indicated that BMP9 conferred resistance to DDP in ovarian cancer cells by inducing EMT. The present study provided valuable insight into the mechanisms of chemotherapy in ovarian cancer and highlighted the potential of BMP9 as a novel therapeutic target for improving cisplatin chemosensitivity.
Collapse
|
12
|
Jin Y, Zheng W, Li L, Huang G, Liu Y, Jiang H, Zhang Y, Tang C. Loss of BMP-10 is correlated with poor survival in ovarian cancer. Pathol Res Pract 2018; 215:121-126. [PMID: 30401582 DOI: 10.1016/j.prp.2018.10.025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 10/07/2018] [Accepted: 10/20/2018] [Indexed: 11/17/2022]
Abstract
INTRODUCTION The expression of bone morphogenetic protein-10 (BMP-10) is downregulated in some cancer types, but its function and mechanism in ovarian cancer remains unclear. MATERIALS AND METHODS BMP-10 expression was detected in ovarian cancer tissues and cell lines by using immunochemistry and western blotting. Prognostic value of BMP-10 was evaluated by Kaplan-Meier curve and Cox regression model. Knockdown or overexpression of BMP-10 was conducted by using specific siRNA or pcDNA-BMP-10 in ovarian cancer cell lines. The biological features induced by BMP-10 were observed by MTT assay, wound-healing and transwell assays. RESULTS BMP-10 expression in ovarian cancer tissues was significantly lower than that in ovarian tissues. Low BMP-10 expression in ovarian cancer tissues was related to advance FIGO stage, higher histologic grade, lymph node metastasis, and peritoneal fluid. Kaplan-Meier analysis revealed that low BMP-10 expression was significantly associated with poor prognosis of patients with ovarian cancer. BMP-10 overexpression or knockdown significantly inhibited or promoted proliferation, migration, and invasion of ovarian cancer cells, respectively. Moreover, administration of neutralizing antibody or human recombinant BMP-10 would reverse these effects on ovarian cancer cells. CONCLUSION Low BMP-10 expression was associated with poor prognosis and progression of ovarian cancer.
Collapse
Affiliation(s)
- Yunfeng Jin
- Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
| | - Wenjie Zheng
- Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
| | - Li Li
- Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
| | - Guoqin Huang
- Department of Obstetrics and Gynecology, Affiliated Maternal and Child Health Care Hospital of Nantong University, Nantong, Jiangsu 226018, China
| | - Ya Liu
- Department of Obstetrics and Gynecology, Affiliated Haian People's Hospital of Nantong University, Nantong, Jiangsu 226600, China
| | - Haiyan Jiang
- Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
| | - Yuexiang Zhang
- Department of Obstetrics and Gynecology, Affiliated Maternal and Child Health Care Hospital of Nantong University, Nantong, Jiangsu 226018, China.
| | - Chunhui Tang
- Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.
| |
Collapse
|
13
|
Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A, Levine H. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol Ther 2018; 194:161-184. [PMID: 30268772 DOI: 10.1016/j.pharmthera.2018.09.007] [Citation(s) in RCA: 199] [Impact Index Per Article: 33.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Cancer metastasis and therapy resistance are the major unsolved clinical challenges, and account for nearly all cancer-related deaths. Both metastasis and therapy resistance are fueled by epithelial plasticity, the reversible phenotypic transitions between epithelial and mesenchymal phenotypes, including epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET). EMT and MET have been largely considered as binary processes, where cells detach from the primary tumor as individual units with many, if not all, traits of a mesenchymal cell (EMT) and then convert back to being epithelial (MET). However, recent studies have demonstrated that cells can metastasize in ways alternative to traditional EMT paradigm; for example, they can detach as clusters, and/or occupy one or more stable hybrid epithelial/mesenchymal (E/M) phenotypes that can be the end point of a transition. Such hybrid E/M cells can integrate various epithelial and mesenchymal traits and markers, facilitating collective cell migration. Furthermore, these hybrid E/M cells may possess higher tumor-initiation and metastatic potential as compared to cells on either end of the EMT spectrum. Here, we review in silico, in vitro, in vivo and clinical evidence for the existence of one or more hybrid E/M phenotype(s) in multiple carcinomas, and discuss their implications in tumor-initiation, tumor relapse, therapy resistance, and metastasis. Together, these studies drive the emerging notion that cells in a hybrid E/M phenotype may occupy 'metastatic sweet spot' in multiple subtypes of carcinomas, and pathways linked to this (these) hybrid E/M state(s) may be relevant as prognostic biomarkers as well as a promising therapeutic targets.
Collapse
Affiliation(s)
- Mohit Kumar Jolly
- Center for Theoretical Biological Physics, Rice University, Houston, TX, USA.
| | - Jason A Somarelli
- Duke Cancer Institute and Department of Medicine, Duke University Medical Center, Durham, USA
| | - Maya Sheth
- Duke Cancer Institute and Department of Medicine, Duke University Medical Center, Durham, USA
| | - Adrian Biddle
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Satyendra C Tripathi
- Department of Clinical Cancer Prevention, UT MD Anderson Cancer Center, Houston, USA
| | - Andrew J Armstrong
- Duke Cancer Institute and Department of Medicine, Duke University Medical Center, Durham, USA
| | - Samir M Hanash
- Department of Clinical Cancer Prevention, UT MD Anderson Cancer Center, Houston, USA
| | - Sharmila A Bapat
- National Center for Cell Science, Savitribai Phule Pune University Campus, Ganeshkhind, Pune, India
| | - Annapoorni Rangarajan
- Department of Molecular Reproduction, Development & Genetics, Indian Institute of Science, Bangalore, India
| | - Herbert Levine
- Center for Theoretical Biological Physics, Rice University, Houston, TX, USA.
| |
Collapse
|
14
|
Peart T, Ramos Valdes Y, Correa RJM, Fazio E, Bertrand M, McGee J, Préfontaine M, Sugimoto A, DiMattia GE, Shepherd TG. Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids. Oncotarget 2016; 6:22424-38. [PMID: 26068970 PMCID: PMC4673173 DOI: 10.18632/oncotarget.4211] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 05/23/2015] [Indexed: 12/12/2022] Open
Abstract
Metastatic epithelial ovarian cancer (EOC) cells can form multicellular spheroids while in suspension and disperse directly throughout the peritoneum to seed secondary lesions. There is growing evidence that EOC spheroids are key mediators of metastasis, and they use specific intracellular signalling pathways to control cancer cell growth and metabolism for increased survival. Our laboratory discovered that AKT signalling is reduced during spheroid formation leading to cellular quiescence and autophagy, and these may be defining features of tumour cell dormancy. To further define the phenotype of EOC spheroids, we have initiated studies of the Liver kinase B1 (LKB1)-5′-AMP-activated protein kinase (AMPK) pathway as a master controller of the metabolic stress response. We demonstrate that activity of AMPK and its upstream kinase LKB1 are increased in quiescent EOC spheroids as compared with proliferating adherent EOC cells. We also show elevated AMPK activity in spheroids isolated directly from patient ascites. Functional studies reveal that treatment with the AMP mimetic AICAR or allosteric AMPK activator A-769662 led to a cytostatic response in proliferative adherent ovarian cancer cells, but they fail to elicit an effect in spheroids. Targeted knockdown of STK11 by RNAi to reduce LKB1 expression led to reduced viability and increased sensitivity to carboplatin treatment in spheroids only, a phenomenon which was AMPK-independent. Thus, our results demonstrate a direct impact of altered LKB1-AMPK signalling function in EOC. In addition, this is the first evidence in cancer cells demonstrating a pro-survival function for LKB1, a kinase traditionally thought to act as a tumour suppressor.
Collapse
Affiliation(s)
- Teresa Peart
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada.,Department of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Yudith Ramos Valdes
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada
| | - Rohann J M Correa
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada.,Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Elena Fazio
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada.,Department of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Monique Bertrand
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada.,Department of Obstetrics & Gynaecology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada.,Department of Oncology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Jacob McGee
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada.,Department of Obstetrics & Gynaecology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Michel Préfontaine
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada.,Department of Obstetrics & Gynaecology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Akira Sugimoto
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada.,Department of Obstetrics & Gynaecology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada.,Department of Oncology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Gabriel E DiMattia
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada.,Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada.,Department of Obstetrics & Gynaecology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada.,Department of Oncology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Trevor G Shepherd
- Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada.,Department of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada.,Department of Obstetrics & Gynaecology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada.,Department of Oncology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada
| |
Collapse
|
15
|
Rafehi S, Ramos Valdes Y, Bertrand M, McGee J, Préfontaine M, Sugimoto A, DiMattia GE, Shepherd TG. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids. Endocr Relat Cancer 2016; 23:147-59. [PMID: 26647384 DOI: 10.1530/erc-15-0383] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/08/2015] [Indexed: 12/23/2022]
Abstract
Epithelial-mesenchymal transition (EMT) serves as a key mechanism driving tumor cell migration, invasion, and metastasis in many carcinomas. Transforming growth factor-beta (TGFβ) signaling is implicated in several steps during cancer pathogenesis and acts as a classical inducer of EMT. Since epithelial ovarian cancer (EOC) cells have the potential to switch between epithelial and mesenchymal states during metastasis, we predicted that modulation of TGFβ signaling would significantly impact EMT and the malignant potential of EOC spheroid cells. Ovarian cancer patient ascites-derived cells naturally underwent an EMT response when aggregating into spheroids, and this was reversed upon spheroid re-attachment to a substratum. CDH1/E-cadherin expression was markedly reduced in spheroids compared with adherent cells, in concert with an up-regulation of several transcriptional repressors, i.e., SNAI1/Snail, TWIST1/2, and ZEB2. Treatment of EOC spheroids with the TGFβ type I receptor inhibitor, SB-431542, potently blocked the endogenous activation of EMT in spheroids. Furthermore, treatment of spheroids with SB-431542 upon re-attachment enhanced the epithelial phenotype of dispersing cells and significantly decreased cell motility and Transwell migration. Spheroid formation was significantly compromised by exposure to SB-431542 that correlated with a reduction in cell viability particularly in combination with carboplatin treatment. Thus, our findings are the first to demonstrate that intact TGFβ signaling is required to control EMT in EOC ascites-derived cell spheroids, and it promotes the malignant characteristics of these structures. As such, we show the therapeutic potential for targeted inhibition of this pathway in ovarian cancer patients with late-stage disease.
Collapse
Affiliation(s)
- Samah Rafehi
- Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Yudith Ramos Valdes
- Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Monique Bertrand
- Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University o
| | - Jacob McGee
- Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Michel Préfontaine
- Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada
| | - Akira Sugimoto
- Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University o
| | - Gabriel E DiMattia
- Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University o
| | - Trevor G Shepherd
- Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University o
| |
Collapse
|
16
|
Ziske MA, Pettee KM, Khaing M, Rubinic K, Eisenmann KM. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids. Biochem Biophys Res Commun 2016; 472:33-9. [PMID: 26898799 DOI: 10.1016/j.bbrc.2016.02.049] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Accepted: 02/14/2016] [Indexed: 01/02/2023]
Abstract
Due to a lack of effective screening or prevention protocol for epithelial ovarian cancer (EOC), there is a critical unmet need to develop therapeutic interventions for EOC treatment. EOC metastasis is unique. Initial dissemination is not primarily hematogenous, yet is facilitated through shedding of primary tumor cells into the peritoneal fluid and accumulating ascites. Increasingly, isolated patient spheroids point to a clinical role for spheroids in EOC metastasis. EOC spheroids are highly invasive structures that disseminate upon peritoneal mesothelium, and visceral tissues including liver and omentum. Selection for this subset of chemoresistant EOC cells could influence disease progression and/or recurrence. Thus, targeting spheroid integrity/structure may improve the chemotherapeutic responsiveness of EOC. We discovered a critical role for mammalian Diaphanous (mDia)-related formin-2 in maintaining EOC spheroid structure. Both mDia2 and the related mDia1 regulate F-actin networks critical to maintain cell-cell contacts and the integrity of multi-cellular epithelial sheets. We investigated if mDia2 functional inhibition via a small molecule inhibitor SMIFH2 combined with chemotherapeutics, such as taxol and cisplatin, inhibits the viability of EOC monolayers and clinically relevant spheroids. SMIFH2-mediated mDia formin inhibition significantly reduced both ES2 and Skov3 EOC monolayer viability while spheroid viability was minimally impacted only at the highest concentrations. Combining either cisplatin or taxol with SMIFH2 did not significantly enhance the effects of either drug alone in ES2 monolayers, while Skov3 monolayers treated with taxol or cisplatin and SMIFH2 showed significant additive inhibition of viability. ES2 spheroids were highly responsive with clear additive anti-viability effects with dual taxol or cisplatin when combined with SMIFH2 treatments. While combined taxol with SMIFH2 in spheroids showed an additive effect relative to single treatments, Skov3 spheroids showed no additive effects from combined cisplatin and SMIFH2 treatments. Our data indicate that mDia formin inhibition combined with taxol to drive enhanced and/or additive anti-viability effects targeting 3D EOC structures, including ES2 and Skov3 spheroids. Combined mDia formin inhibition with cisplatin may be most effective in EOC spheroids where cisplatin sensitivity is retained at moderate levels, such as ES2 cells.
Collapse
Affiliation(s)
- Megan A Ziske
- Department of Biochemistry and Cancer Biology, University of Toledo Health Science Campus, Mail Stop 1010, 3000 Arlington Avenue, Toledo, OH 43614, USA
| | - Krista M Pettee
- Department of Biochemistry and Cancer Biology, University of Toledo Health Science Campus, Mail Stop 1010, 3000 Arlington Avenue, Toledo, OH 43614, USA
| | - MaNada Khaing
- Department of Biochemistry and Cancer Biology, University of Toledo Health Science Campus, Mail Stop 1010, 3000 Arlington Avenue, Toledo, OH 43614, USA
| | - Kaitlin Rubinic
- Department of Biochemistry and Cancer Biology, University of Toledo Health Science Campus, Mail Stop 1010, 3000 Arlington Avenue, Toledo, OH 43614, USA
| | - Kathryn M Eisenmann
- Department of Biochemistry and Cancer Biology, University of Toledo Health Science Campus, Mail Stop 1010, 3000 Arlington Avenue, Toledo, OH 43614, USA.
| |
Collapse
|
17
|
Hover LD, Young CD, Bhola NE, Wilson AJ, Khabele D, Hong CC, Moses HL, Owens P. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Lett 2015; 368:79-87. [PMID: 26235139 DOI: 10.1016/j.canlet.2015.07.032] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Revised: 07/16/2015] [Accepted: 07/25/2015] [Indexed: 01/06/2023]
Abstract
The bone morphogenetic protein (BMP) pathway belonging to the Transforming Growth Factor beta (TGFβ) family of secreted cytokines/growth factors is an important regulator of cancer. BMP ligands have been shown to play both tumor suppressive and promoting roles in human cancers. We have found that BMP ligands are amplified in human ovarian cancers and that BMP receptor expression correlates with poor progression-free-survival (PFS). Furthermore, active BMP signaling has been observed in human ovarian cancer tissue. We also determined that ovarian cancer cell lines have active BMP signaling in a cell autonomous fashion. Inhibition of BMP signaling with a small molecule receptor kinase antagonist is effective at reducing ovarian tumor sphere growth. Furthermore, BMP inhibition can enhance sensitivity to Cisplatin treatment and regulates gene expression involved in platinum resistance in ovarian cancer. Overall, these studies suggest targeting the BMP pathway as a novel source to enhance chemo-sensitivity in ovarian cancer.
Collapse
Affiliation(s)
- Laura D Hover
- Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA
| | - Christian D Young
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Neil E Bhola
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Andrew J Wilson
- Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA; Department of Obstetrics and Gynecology, Vanderbilt University, Nashville, TN, USA
| | - Dineo Khabele
- Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA; Department of Obstetrics and Gynecology, Vanderbilt University, Nashville, TN, USA
| | - Charles C Hong
- Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA; Department of Medicine, Cardiovascular, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Harold L Moses
- Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Philip Owens
- Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
| |
Collapse
|
18
|
Ali JL, Lagasse BJ, Minuk AJ, Love AJ, Moraya AI, Lam L, Arthur G, Gibson SB, Morrison LC, Werbowetski-Ogilvie TE, Fu Y, Nachtigal MW. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells. Int J Cancer 2014; 136:E455-69. [PMID: 25227893 DOI: 10.1002/ijc.29220] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Revised: 08/21/2014] [Accepted: 09/10/2014] [Indexed: 12/11/2022]
Abstract
Inherent or acquired drug resistance is a major contributor to epithelial ovarian cancer (EOC) mortality. Novel drugs or drug combinations that produce EOC cell death or resensitize drug resistant cells to standard chemotherapy may improve patient treatment. After conducting drug tolerability studies for the multikinase inhibitors dorsomorphin (DM) and it is structural analogue LDN-193189 (LDN), these drugs were tested in a mouse intraperitoneal xenograft model of EOC. DM significantly increased survival, whereas LDN showed a trend toward increased survival. In vitro experiments using cisplatin (CP)-resistant EOC cell lines, A2780-cp or SKOV3, we determined that pretreatment or cotreatment with DM or LDN resensitized cells to the killing effect of CP or carboplatin (CB). DM was capable of blocking EOC cell cycle and migration, whereas LDN produced a less pronounced effect on cell cycle and no effect on migration. Subsequent analyses using primary human EOC cell samples or additional established EOC cells lines showed that DM or LDN induced a dose-dependent autophagic or cell death response, respectively. DM induced a characteristic morphological change with the appearance of numerous LC3B-containing acidic vacuoles and an increase in LC3BII levels. This was coincident with a decrease in cell growth and the altered cell cycle consistent with DM-induced cytostasis. By contrast, LDN produced a caspase 3-independent, reactive oxygen species-dependent cell death. Overall, DM and LDN possess drug characteristics suitable for adjuvant agents used to treat chemotherapy-sensitive and -resistant EOC.
Collapse
Affiliation(s)
- Jennifer L Ali
- Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Wang L, Zhu MJ, Ren AM, Wu HF, Han WM, Tan RY, Tu RQ. A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One 2014; 9:e96472. [PMID: 24816756 PMCID: PMC4015980 DOI: 10.1371/journal.pone.0096472] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2013] [Accepted: 04/08/2014] [Indexed: 11/19/2022] Open
Abstract
Epithelial ovarian cancer (EOC) is the most common gynecologic malignancy. To identify the micro-ribonucleic acids (miRNAs) expression profile in EOC tissues that may serve as a novel diagnostic biomarker for EOC detection, the expression of 1722 miRNAs from 15 normal ovarian tissue samples and 48 ovarian cancer samples was profiled by using a quantitative real-time polymerase chain reaction (qRT-PCR) assay. A ten-microRNA signature (hsa-miR-1271-5p, hsa-miR-574-3p, hsa-miR-182-5p, hsa-miR-183-5p, hsa-miR-96-5p, hsa-miR-15b-5p, hsa-miR-182-3p, hsa-miR-141-5p, hsa-miR-130b-5p, and hsa-miR-135b-3p) was identified to be able to distinguish human ovarian cancer tissues from normal tissues with 97% sensitivity and 92% specificity. Two miRNA clusters of miR183-96-183 (miR-96-5p, and miR-182, miR183) and miR200 (miR-141-5p, miR200a, b, c and miR429) are significantly up-regulated in ovarian cancer tissue samples compared to those of normal tissue samples, suggesting theses miRNAs may be involved in ovarian cancer development.
Collapse
Affiliation(s)
- Lin Wang
- Department of Obstetrics and Gynecology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China
| | | | - Ai-Min Ren
- Department of Obstetrics and Gynecology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China
| | - Hong-Fei Wu
- Biovue Technology (China) Ltd., Shanghai, China
| | - Wu-Mei Han
- Biovue Technology (China) Ltd., Shanghai, China
| | | | - Rui-Qin Tu
- Department of Obstetrics and Gynecology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
20
|
Girard YK, Wang C, Ravi S, Howell MC, Mallela J, Alibrahim M, Green R, Hellermann G, Mohapatra SS, Mohapatra S. A 3D fibrous scaffold inducing tumoroids: a platform for anticancer drug development. PLoS One 2013; 8:e75345. [PMID: 24146752 PMCID: PMC3797770 DOI: 10.1371/journal.pone.0075345] [Citation(s) in RCA: 91] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2013] [Accepted: 08/12/2013] [Indexed: 01/18/2023] Open
Abstract
The development of a suitable three dimensional (3D) culture system for anticancer drug development remains an unmet need. Despite progress, a simple, rapid, scalable and inexpensive 3D-tumor model that recapitulates in vivo tumorigenesis is lacking. Herein, we report on the development and characterization of a 3D nanofibrous scaffold produced by electrospinning a mixture of poly(lactic-co-glycolic acid) (PLGA) and a block copolymer of polylactic acid (PLA) and mono-methoxypolyethylene glycol (mPEG) designated as 3P. Cancer cells cultured on the 3P scaffold formed tight irregular aggregates similar to in vivo tumors, referred to as tumoroids that depended on the topography and net charge of the scaffold. 3P scaffolds induced tumor cells to undergo the epithelial-to-mesenchymal transition (EMT) as demonstrated by up-regulation of vimentin and loss of E-cadherin expression. 3P tumoroids showed higher resistance to anticancer drugs than the same tumor cells grown as monolayers. Inhibition of ERK and PI3K signal pathways prevented EMT and reduced tumoroid formation, diameter and number. Fine needle aspirates, collected from tumor cells implanted in mice when cultured on 3P scaffolds formed tumoroids, but showed decreased sensitivity to anticancer drugs, compared to tumoroids formed by direct seeding. These results show that 3P scaffolds provide an excellent platform for producing tumoroids from tumor cell lines and from biopsies and that the platform can be used to culture patient biopsies, test for anticancer compounds and tailor a personalized cancer treatment.
Collapse
Affiliation(s)
- Yvonne K. Girard
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Nanomedicine Research Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Chunyan Wang
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Nanomedicine Research Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Sowndharya Ravi
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Nanomedicine Research Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Mark C. Howell
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Nanomedicine Research Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Jaya Mallela
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Nanomedicine Research Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Mahmoud Alibrahim
- Chemical and Biomedical Engineering Department, University of South Florida, Tampa, Florida, United States of America
| | - Ryan Green
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Nanomedicine Research Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Gary Hellermann
- USF Nanomedicine Research Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Shyam S. Mohapatra
- USF Nanomedicine Research Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Subhra Mohapatra
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Nanomedicine Research Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America
- * E-mail:
| |
Collapse
|
21
|
Kipps E, Tan DSP, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013; 13:273-82. [PMID: 23426401 PMCID: PMC4673904 DOI: 10.1038/nrc3432] [Citation(s) in RCA: 399] [Impact Index Per Article: 36.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer, but also provides a wealth of opportunities for translational research. The accessibility of ascitic fluid and its cellular components make it an excellent source of tumour tissue for the investigation of prognostic and predictive biomarkers, pharmacodynamic markers and for molecular profiling analysis. In this Opinion article, we discuss recent advances in our understanding of its pathophysiology, the development of new methods to characterize its molecular features and how these findings can be used to improve the treatment of malignant ascites, particularly in the context of ovarian cancer.
Collapse
Affiliation(s)
- Emma Kipps
- The Institute of Cancer Research/Royal Marsden Hospital, Medicine, Downs Road, Sutton SM2 5PT, UK
| | | | | |
Collapse
|
22
|
Sun D, Haddad R, Kraniak JM, Horne SD, Tainsky MA. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST. Mol Cancer Res 2013; 11:616-27. [PMID: 23423222 DOI: 10.1158/1541-7786.mcr-12-0593] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Malignant peripheral nerve sheath tumor (MPNST) is a type of soft tissue sarcoma that occurs in carriers of germline mutations in Nf1 gene as well as sporadically. Neurofibromin, encoded by the Nf1 gene, functions as a GTPase-activating protein (GAP) whose mutation leads to activation of wt-RAS and mitogen-activated protein kinase (MAPK) signaling in neurofibromatosis type I (NF1) patients' tumors. However, therapeutic targeting of RAS and MAPK have had limited success in this disease. In this study, we modulated NRAS, mitogen-activated protein/extracellular signal-regulated kinase (MEK)1/2, and neurofibromin levels in MPNST cells and determined gene expression changes to evaluate the regulation of signaling pathways in MPNST cells. Gene expression changes due to neurofibromin modulation but independent of NRAS and MEK1/2 regulation in MPNST cells indicated bone morphogenetic protein 2 (Bmp2) signaling as a key pathway. The BMP2-SMAD1/5/8 pathway was activated in NF1-associated MPNST cells and inhibition of BMP2 signaling by LDN-193189 or short hairpin RNA (shRNA) to BMP2 decreased the motility and invasion of NF1-associated MPNST cells. The pathway-specific gene changes provide a greater understanding of the complex role of neurofibromin in MPNST pathology and novel targets for drug discovery.
Collapse
Affiliation(s)
- Daochun Sun
- Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Wayne State University, Detroit, Michigan 48201, USA
| | | | | | | | | |
Collapse
|
23
|
Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, Schwartz GN, Wells WA, Sempere LF, Yu PB, DiRenzo J. ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res 2012; 73:1020-30. [PMID: 23243027 DOI: 10.1158/0008-5472.can-12-2862] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Genetic analysis of TP63 indicates that ΔNp63 isoforms are required for preservation of regenerative stasis within diverse epithelial tissues. In squamous carcinomas, TP63 is commonly amplified, and ΔNp63α confers a potent survival advantage. Genome-wide occupancy studies show that ΔNp63 promotes bidirectional target gene regulation by binding more than 5,000 sites throughout the genome; however, the subset of targets mediating discreet activities of TP63 remains unclear. We report that ΔNp63α activates bone morphogenic proteins (BMP) signaling by inducing the expression of BMP7. Immunohistochemical analysis indicates that hyperactivation of BMP signaling is common in human breast cancers, most notably in the basal molecular subtype, as well as in several mouse models of breast cancer. Suppression of BMP signaling in vitro with LDN193189, a small-molecule inhibitor of BMP type I receptor kinases, represses clonogenicity and diminishes the cancer stem cell-enriched ALDH1(+) population. Importantly, LDN193189 blocks reconstitution of mixed ALDH1(+)/ALDH1(-) cultures indicating that BMP signaling may govern aspects of cellular plasticity within tumor hierarchies. These results show that BMP signaling enables reversion of committed populations to a stem-like state, potentially supporting progression and maintenance of tumorigenesis. Treatment of a mouse model of breast cancer with LDN193189 caused reduced expression of markers associated with epithelial-to-mesenchymal transition (EMT). Furthermore, in vivo limiting dilution analysis assays revealed that LDN193189 treatment suppressed tumor-initiating capacity and increased tumor latency. These studies support a model in which ΔNp63α-mediated activation of BMP signaling governs epithelial cell plasticity, EMT, and tumorigenicity during breast cancer initiation and progression.
Collapse
Affiliation(s)
- Amanda L Balboni
- Program in Experimental and Molecular Medicine, Department of Pharmacology and Toxicology, The Audrey and Theodor Geisel School of Medicine at Dartmouth, NH 03755, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|